Dr. Jonathan Milner

Dr. Jonathan Milner is a seasoned entrepreneur and investor, best known for founding Abcam plc in 1998, a leading supplier of antibody-based research reagents. His journey began with a doctorate in Molecular Genetics from Leicester University, followed by post-doctoral research at the University of Cambridge, where he identified the market need for high-quality antibodies to support protein interaction studies. This insight led to the establishment of Abcam, which has since become a prominent player in the biotechnology sector. Beyond Abcam, Dr. Milner has been instrumental in supporting over 80 companies, providing investment, mentoring, and assistance in taking three technology companies public on the London AIM Stock Exchange. His commitment to advancing the life sciences industry is further demonstrated through his roles as a non-executive director of Healx, Shift Bioscience, and Syndicate Room, and as chairman of Axol Bioscience, Cambridge Allergy, and PhoreMost. Additionally, he co-founded the Milner Centre for Evolution at the University of Bath and the Milner Institute for Therapeutics at the University of Cambridge, reflecting his dedication to fostering scientific research and innovation. In 2023, Dr. Milner opposed Danaher's proposed $5.7 billion acquisition of Abcam, believing the offer undervalued the company. He advocated for maintaining Abcam's independence and enhancing shareholder value through strategic initiatives, including re-listing on the London Stock Exchange. His active involvement in Abcam's strategic direction underscores his commitment to the company's growth and success.

Strong management team, Innovative technology, Scalable business model, Clear path to profitability, Competitive market positioning, Potential for significant impact in the healthcare or biotechnology sectors, Alignment with Dr. Milner's values and investment philosophy